Use of atazanavir to reduce plasma LDL and/or triclyceride levels in an HIV-infected patient

摘要

Disclosed is the use of atazanavir in the manufacture of a medicament for use in place of a HIV protease inhibitor to reduce elevated plasma LDL and/or triglyceride levels in an HIV-infected patient resulting from therapy with one or more HIV protease inhibitors.